BFM-type chemotherapy for childhood acute lymphoblastic leukemia impairs pubertal spurt and causes moderate adult height loss

S. Milani, M. Maghnie, V. Conter, C. Messina, E. Barisone, G. Cosi, O. Ziino, F. Locatelli, Maurizio Aricò

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives. To assess the pattern of somatic development in subjects who recovered from childhood acute lymphoblastic leukemia and to define the role of cranial irradiation and intensive chemotherapy. Methods. We investigated 85 patients, 46 girls (mean age at diagnosis 6.3 years, at last follow-up 13.8 years) and 39 boys (mean age at diagnosis 7.8 years, at last follow-up 15.5 years) treated in the AIEOP-ALL-88 study with BFM-type, intensive chemotherapy; high-risk patients (n = 30) received cranial irradiation as well. Growth profiles (height, weight, growth velocity, BMI) were characterized. Results. Height-standard deviation score (SDS) from target height at diagnosis was +0.64 (girls) and +0.60 (boys), which turned into +0.24 and +0.22 after a mean follow-up of 7.5 and 7.7 years. Thus, there was a mild decrease in height-SDS by -0.39 ± 0.08 (mean ± SE) in both groups. Weight-SDS increased by 0.33 ± 0.17 (girls) and 0.63 ± 0.22 (boys), particularly in patients aged below 7 years. Height growth did not depend on age at treatment. Velocity curves widely differed between ALL and controls, mainly in pubertal spurt from take-off to peak velocity. Conclusions. Subjects who recovered from childhood all with BFM-type chemotherapy are prone to moderate height loss - more evident in females, and to overweight - especially in irradiated males.

Original languageEnglish
Pages (from-to)420-426
Number of pages7
JournalItalian Journal of Pediatrics
Volume29
Issue number6
Publication statusPublished - Dec 2003

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cranial Irradiation
Drug Therapy
Growth
Weights and Measures
Therapeutics

Keywords

  • Acute lymphoblastic leukemia
  • Growth

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

BFM-type chemotherapy for childhood acute lymphoblastic leukemia impairs pubertal spurt and causes moderate adult height loss. / Milani, S.; Maghnie, M.; Conter, V.; Messina, C.; Barisone, E.; Cosi, G.; Ziino, O.; Locatelli, F.; Aricò, Maurizio.

In: Italian Journal of Pediatrics, Vol. 29, No. 6, 12.2003, p. 420-426.

Research output: Contribution to journalArticle

Milani, S. ; Maghnie, M. ; Conter, V. ; Messina, C. ; Barisone, E. ; Cosi, G. ; Ziino, O. ; Locatelli, F. ; Aricò, Maurizio. / BFM-type chemotherapy for childhood acute lymphoblastic leukemia impairs pubertal spurt and causes moderate adult height loss. In: Italian Journal of Pediatrics. 2003 ; Vol. 29, No. 6. pp. 420-426.
@article{821f91ef47a9419fb8514c0bb9575f9f,
title = "BFM-type chemotherapy for childhood acute lymphoblastic leukemia impairs pubertal spurt and causes moderate adult height loss",
abstract = "Objectives. To assess the pattern of somatic development in subjects who recovered from childhood acute lymphoblastic leukemia and to define the role of cranial irradiation and intensive chemotherapy. Methods. We investigated 85 patients, 46 girls (mean age at diagnosis 6.3 years, at last follow-up 13.8 years) and 39 boys (mean age at diagnosis 7.8 years, at last follow-up 15.5 years) treated in the AIEOP-ALL-88 study with BFM-type, intensive chemotherapy; high-risk patients (n = 30) received cranial irradiation as well. Growth profiles (height, weight, growth velocity, BMI) were characterized. Results. Height-standard deviation score (SDS) from target height at diagnosis was +0.64 (girls) and +0.60 (boys), which turned into +0.24 and +0.22 after a mean follow-up of 7.5 and 7.7 years. Thus, there was a mild decrease in height-SDS by -0.39 ± 0.08 (mean ± SE) in both groups. Weight-SDS increased by 0.33 ± 0.17 (girls) and 0.63 ± 0.22 (boys), particularly in patients aged below 7 years. Height growth did not depend on age at treatment. Velocity curves widely differed between ALL and controls, mainly in pubertal spurt from take-off to peak velocity. Conclusions. Subjects who recovered from childhood all with BFM-type chemotherapy are prone to moderate height loss - more evident in females, and to overweight - especially in irradiated males.",
keywords = "Acute lymphoblastic leukemia, Growth",
author = "S. Milani and M. Maghnie and V. Conter and C. Messina and E. Barisone and G. Cosi and O. Ziino and F. Locatelli and Maurizio Aric{\`o}",
year = "2003",
month = "12",
language = "English",
volume = "29",
pages = "420--426",
journal = "Italian Journal of Pediatrics",
issn = "1720-8424",
publisher = "BioMed Central Ltd.",
number = "6",

}

TY - JOUR

T1 - BFM-type chemotherapy for childhood acute lymphoblastic leukemia impairs pubertal spurt and causes moderate adult height loss

AU - Milani, S.

AU - Maghnie, M.

AU - Conter, V.

AU - Messina, C.

AU - Barisone, E.

AU - Cosi, G.

AU - Ziino, O.

AU - Locatelli, F.

AU - Aricò, Maurizio

PY - 2003/12

Y1 - 2003/12

N2 - Objectives. To assess the pattern of somatic development in subjects who recovered from childhood acute lymphoblastic leukemia and to define the role of cranial irradiation and intensive chemotherapy. Methods. We investigated 85 patients, 46 girls (mean age at diagnosis 6.3 years, at last follow-up 13.8 years) and 39 boys (mean age at diagnosis 7.8 years, at last follow-up 15.5 years) treated in the AIEOP-ALL-88 study with BFM-type, intensive chemotherapy; high-risk patients (n = 30) received cranial irradiation as well. Growth profiles (height, weight, growth velocity, BMI) were characterized. Results. Height-standard deviation score (SDS) from target height at diagnosis was +0.64 (girls) and +0.60 (boys), which turned into +0.24 and +0.22 after a mean follow-up of 7.5 and 7.7 years. Thus, there was a mild decrease in height-SDS by -0.39 ± 0.08 (mean ± SE) in both groups. Weight-SDS increased by 0.33 ± 0.17 (girls) and 0.63 ± 0.22 (boys), particularly in patients aged below 7 years. Height growth did not depend on age at treatment. Velocity curves widely differed between ALL and controls, mainly in pubertal spurt from take-off to peak velocity. Conclusions. Subjects who recovered from childhood all with BFM-type chemotherapy are prone to moderate height loss - more evident in females, and to overweight - especially in irradiated males.

AB - Objectives. To assess the pattern of somatic development in subjects who recovered from childhood acute lymphoblastic leukemia and to define the role of cranial irradiation and intensive chemotherapy. Methods. We investigated 85 patients, 46 girls (mean age at diagnosis 6.3 years, at last follow-up 13.8 years) and 39 boys (mean age at diagnosis 7.8 years, at last follow-up 15.5 years) treated in the AIEOP-ALL-88 study with BFM-type, intensive chemotherapy; high-risk patients (n = 30) received cranial irradiation as well. Growth profiles (height, weight, growth velocity, BMI) were characterized. Results. Height-standard deviation score (SDS) from target height at diagnosis was +0.64 (girls) and +0.60 (boys), which turned into +0.24 and +0.22 after a mean follow-up of 7.5 and 7.7 years. Thus, there was a mild decrease in height-SDS by -0.39 ± 0.08 (mean ± SE) in both groups. Weight-SDS increased by 0.33 ± 0.17 (girls) and 0.63 ± 0.22 (boys), particularly in patients aged below 7 years. Height growth did not depend on age at treatment. Velocity curves widely differed between ALL and controls, mainly in pubertal spurt from take-off to peak velocity. Conclusions. Subjects who recovered from childhood all with BFM-type chemotherapy are prone to moderate height loss - more evident in females, and to overweight - especially in irradiated males.

KW - Acute lymphoblastic leukemia

KW - Growth

UR - http://www.scopus.com/inward/record.url?scp=1242272045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242272045&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 420

EP - 426

JO - Italian Journal of Pediatrics

JF - Italian Journal of Pediatrics

SN - 1720-8424

IS - 6

ER -